Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Kratos Receives New Hypersonic System Program Award with Total Potential Value of Approximately $100 Million
-
Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025
-
FOREWARN to Provide Identity Verification Services to Greater Baltimore Board of REALTORS® to Promote Agent Safety
-
Wondr Health Expands Interventions to Address and Prevent High-Cost Chronic Conditions
-
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations
-
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
-
COMSTOCK RESOURCES, INC. ANNOUNCES FOURTH QUARTER 2024 EARNINGS DATE AND CONFERENCE CALL INFORMATION
-
SLR Investment Corp. Schedules the Release of its Financial Results for the Quarter and Fiscal Year Ended December 31, 2024
-
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
The RoyaLand Company Ltd. to Deliver a Live Investor Presentation via the Skyline Signature Series™
-
VEON to List Kyivstar on Nasdaq in New York, Signs Letter of Intent with Cohen Circle
-
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
-
STMicroelectronics Announces Status of Common Share Repurchase Program
-
genXtraits Inc. and Solis Agrosciences enter collaboration agreement
-
VivoPower’s Caret Digital Secures CAD$140m Definitive Binding Investment Commitment from Global Alternative Investment Group, GEM Global Yield LLC SCS
-
MCI Study: Brain Exercises Drive Cognitive and Functional Gains in Pre-Dementia Patients
-
Arcadia Enables Healthcare Providers to Deliver Precision Medicine at Scale
-
Act III Holdings Announces Strategic Investment in Honest Greens Barcelona
-
DTE Energy spends $3.3 billion with Michigan suppliers in 2024
-
Celestica Q4 2024 Financial Results and Conference Call Thursday, January 30, 2025
-
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
-
Lifeward Cancels Its Extraordinary General Meeting of Shareholders
-
Wearable Devices Gains Global Recognition at CES 2025 for Innovation in Neural Gesture-Control Technology
-
Rock Samples Return Grades up to 0.51% copper (Cu) from the Rayfield Copper-Gold Property, South-Central British Columbia
-
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
-
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
-
Amalgamated Financial Corp. Announces Fourth Quarter and Full Year 2024 Earnings Conference Call
-
Postal Realty Trust, Inc. Provides Fourth Quarter and Full Year 2024 Update
-
Rio2 Provides Fenix Gold Mine Construction Update
-
Traxys and HNK Alpha Execute First Nickel Sulphate Futures Block Trade on Abaxx Commodity Futures Exchange and Clearinghouse
-
Western Resources Corp. Provides Bi-weekly MCTO Status Update
-
RBC iShares Expands Access to BlackRock’s Bitcoin ETP Platform
-
Mandalay Resources Delivers Strong Q4 Gold and Antimony Performance, Achieves Top End of 2024 Production Guidance Leading to $76 Million Cash Balance
-
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
-
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
-
URBN Reports Record Holiday Sales
-
22nd Century Stands Ready to Support the Adoption of FDA Proposed Tobacco Product Standard to Mandate Reduced Nicotine Content in Cigarettes with its VLN Cigarettes
-
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
-
Arbutus Provides 2025 Corporate and Financial Update
-
Lower Colorado River Authority Widens Wireless Communications Capabilities with Additional Spectrum Licenses from Anterix
-
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
-
MNP Consumer Debt Index Plunges to 79 Points, the Second-Lowest Level Ever Recorded (-10pts)
-
Alliance Witan PLC - Net Asset Value
-
Form 8.3 - [ALLIANCE PHARMA PLC - Opening Disclosure - 10 01 2025] - (CGAML)
-
Form 8.3 - [ALLIANCE PHARMA PLC - 10 01 2025] - (CGWL)
-
EDIBLE GARDEN Signs Non-Binding Letter of Intent to Acquire NARAYAN GROUP to Expand into the European and North American Markets
-
Flow Capital Appoints Brian Beattie to its Board of Directors
-
Form 8.3 - [LOUNGERS PLC - 10 01 2025] - (CGWL)
-
Form 8.3 - [LEARNING TECHNOLOGIES GROUP PLC - 10 01 2025] - (CGWL)
-
Patent and Trademark Office Issues Ensemble’s Latest Patent – Using AI to Improve Clinician and Patient Experience
